RxDoctor Payments Data

Benjamin Teller, OD

Optometrist · Chevy Chase, MDNPI 1447282702

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,852in general payments, 2019–2025

Across 161 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$632
  • Alcon$551
  • Bausch & Lomb Americas Inc.$528
  • Novartis$320
  • Tarsus Pharmaceuticals, Inc.$266
  • Oyster Point Pharma, Inc.$261
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,67495%
  • Gifts$170%
  • Entertainment$1604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,852 in reported general payments places this provider in the 90th percentile of 790 optometrist providers in Maryland.

See all optometrist providers in Maryland

Medicare billing

Part B allowed, 2024
$82,266
Medicare patients
281
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast51$61,604
RestasisCyclosporine28$27,697
VyzultaLatanoprostene Bunod51$20,921
CombiganBrimonidine Tartrate/Timolol23$6,305
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,222
Latanoprost63$468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$528$82,525102 claims
AbbVieRestasis, Combigan$152$34,00251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 optometrist providers in Maryland.

Other optometrist in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →